Form 4: Amgen EVP Murdo Gordon Reports Acquisition of Common Stock and Stock Options

Murdo Gordon, EVP of Global Commercial Operations at Amgen, reports the acquisition of common stock and stock options, including restricted stock units, dividend equivalents, and non-qualified stock options.

Summary

• Murdo Gordon, an EVP at Amgen, filed a Form 4 detailing changes in beneficial ownership.
• On May 6, 2025, Gordon acquired 3,919 shares of Amgen common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Gordon beneficially owns 49,985 shares of Amgen common stock, including 442 Dividend Equivalents.
• Gordon also acquired 25,334 non-qualified stock options with an exercise price of $270.44, vesting in four equal annual installments starting May 6, 2026.
• The stock options expire on May 6, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating executive compensation, which doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of stock and stock options by an executive could be seen as a positive sign of confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the stock options and RSUs extends into the future.

Industry Context

Executive stock ownership is a common practice in publicly traded companies like Amgen. It aligns the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices in the biotechnology industry, used to incentivize and retain key executives.
• Companies like Gilead Sciences, Biogen, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a top executive.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Common Stock, Amgen, Gordon, Acquisition